Axsome Therapeutics, a biopharmaceutical company focused on central nervous system disorders, disclosed that its CEO, Herriot Tabuteau, sold shares totaling approximately $10.5 million. The transaction was reported in a Form 4 filing with the U.S. Securities and Exchange Commission (SEC) on August 6, 2026.
According to the filing, the sales occurred on August 4 and 5, 2026, at prices ranging from $85.00 to $87.50 per share. The exact number of shares sold was not disclosed in the initial report, but the total value was confirmed at $10.5 million.
This insider sale comes as Axsome continues to market its lead product, Auvelity, for major depressive disorder, and Sunosi for narcolepsy and obstructive sleep apnea. The company has not issued any official statement regarding the CEO's stock sale.
Insider sales are common and can be motivated by personal financial planning, diversification, or tax obligations. Investors often monitor such transactions for signals about management's confidence in the company's future prospects.
